These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22536975)

  • 21. Metronomic chemotherapy and immunotherapy in cancer treatment.
    Chen YL; Chang MC; Cheng WF
    Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concise review: engineering the fusion of cytokines for the modulation of immune cellular responses in cancer and autoimmune disorders.
    Ng S; Galipeau J
    Stem Cells Transl Med; 2015 Jan; 4(1):66-73. PubMed ID: 25391644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pure multiplicative stochastic resonance of a theoretical anti-tumor model with seasonal modulability.
    Zhong WR; Shao YZ; He ZH
    Phys Rev E Stat Nonlin Soft Matter Phys; 2006 Jun; 73(6 Pt 1):060902. PubMed ID: 16906802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapies and Combination Strategies for Immuno-Oncology.
    Barbari C; Fontaine T; Parajuli P; Lamichhane N; Jakubski S; Lamichhane P; Deshmukh RR
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of interleukin-21 immunotherapeutic strategies.
    Cappuccio A; Elishmereni M; Agur Z
    J Theor Biol; 2007 Sep; 248(2):259-66. PubMed ID: 17574601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eradication-resolution dynamics with stochastic flare-ups.
    van den Berg HA; Duncombe ZA
    J Theor Biol; 2010 Jun; 264(3):962-70. PubMed ID: 20226791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukins and cancer immunotherapy.
    Yoshimoto T; Morishima N; Okumura M; Chiba Y; Xu M; Mizuguchi J
    Immunotherapy; 2009 Sep; 1(5):825-44. PubMed ID: 20636026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modeling Pancreatic Cancer Dynamics with Immunotherapy.
    Hu X; Ke G; Jang SR
    Bull Math Biol; 2019 Jun; 81(6):1885-1915. PubMed ID: 30843136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
    Gajewski TF
    Semin Oncol; 2015 Aug; 42(4):663-71. PubMed ID: 26320069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.
    Wu J; Waxman DJ
    Cancer Lett; 2018 Apr; 419():210-221. PubMed ID: 29414305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatments.
    Pusuluri A; Wu D; Mitragotri S
    J Control Release; 2019 Jul; 305():130-154. PubMed ID: 31004668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
    Hosseinkhani N; Derakhshani A; Kooshkaki O; Abdoli Shadbad M; Hajiasgharzadeh K; Baghbanzadeh A; Safarpour H; Mokhtarzadeh A; Brunetti O; Yue SC; Silvestris N; Baradaran B
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting iNOS to increase efficacy of immunotherapies.
    Ekmekcioglu S; Grimm EA; Roszik J
    Hum Vaccin Immunother; 2017 May; 13(5):1105-1108. PubMed ID: 28121247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.
    Jespersen H; Lindberg MF; Donia M; Söderberg EMV; Andersen R; Keller U; Ny L; Svane IM; Nilsson LM; Nilsson JA
    Nat Commun; 2017 Sep; 8(1):707. PubMed ID: 28955032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy.
    Li W; Peng A; Wu H; Quan Y; Li Y; Lu L; Cui M
    Front Immunol; 2020; 11():601497. PubMed ID: 33408716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toward integrative cancer immunotherapy: targeting the tumor microenvironment.
    Emens LA; Silverstein SC; Khleif S; Marincola FM; Galon J
    J Transl Med; 2012 Apr; 10():70. PubMed ID: 22490302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adoptive cellular therapy of malignancy.
    Chang AE; Geiger JD; Sondak VK; Shu S
    Arch Surg; 1993 Nov; 128(11):1281-90. PubMed ID: 8239992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3D discrete angiogenesis dynamic model and stochastic simulation for the assessment of blood perfusion coefficient and impact on heat transfer between nanoparticles and malignant tumors.
    Yifat J; Gannot I
    Microvasc Res; 2015 Mar; 98():197-217. PubMed ID: 24462603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
    Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
    Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell transfer-based immunotherapies in cancer: A review.
    Gorabi AM; Hajighasemi S; Sathyapalan T; Sahebkar A
    IUBMB Life; 2020 Apr; 72(4):790-800. PubMed ID: 31633881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.